TransMedics (TMDX) is a publicly traded Healthcare sector company. As of July 6, 2026, TMDX trades at $72.09 with a market cap of $2.38B and a P/E ratio of 13.64. TMDX moved +4.98% today. Year to date, TMDX is -43.52%; over the trailing twelve months it is -46.07%. Its 52-week range spans $55.00 to $156.00. Analyst consensus is buy with an average price target of $120.25. Rallies surfaces TMDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for TMDX, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $72.09 |
| Market Cap | $2.38B |
| P/E Ratio | 13.64 |
| EPS | $5.05 |
| Dividend Yield | 0.00% |
| 52-Week High | $156.00 |
| 52-Week Low | $55.00 |
| Volume | 349.72K |
| Avg Volume | 0 |
| Revenue (TTM) | $635.89M |
| Net Income | $171.92M |
| Gross Margin | 59.09% |
9 analysts cover TMDX: 0 strong buy, 6 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $120.25.